Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Microbiotica logo — The microbiome is a new approach to medicine, offering poten...

Microbiotica

The microbiome is a new approach to medicine, offering potential for significant advancements. Microbiotica aims to remove translation challenges.

Founded 2016 United Kingdom Cambridge, United Kingdom 49 employees Venture round Total: $62.00M Biotechnology, Health Care +1

General Information

Company Name Microbiotica
Founded Year 2016
Location United Kingdom Cambridge, United Kingdom
Employees 49
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Microbiotica . To contact Microbiotica , visit microbiotica.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Microbiotica compare?

A PDF of Microbiotica and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Microbiotica soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

In The News Oct 16, 2026

Featured on Eu-startups: Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molec...

Get alerts when Microbiotica shows new signals

About Microbiotica

Microbiotica is a biotechnology company founded in 2016, headquartered in the United Kingdom. The company focuses on leveraging the microbiome as a novel approach to medicine, aiming to address translation challenges in the field. With a background rooted in a decade-long investment at the Wellcome Sanger Institute, Microbiotica boasts unparalleled capabilities in microbiome analysis linked to patient phenotype. They are considered a global leader in gut bacterial culturing, equipped with a world-leading microbiome Culture Collection, proprietary Reference Genome Database, and advanced microbiome bioinformatics. The company's strengths extend to the realm of microbiome/host biology and the preclinical development of bacterial products. Noteworthy is their pipeline of highly differentiated clinically-derived products, encompassing Live Bacterial Therapeutics and Biomarkers in areas such as IBD, Immuno-oncology, and Gut Epithelial Barrier Repair. Collaborations with prestigious entities like Cancer Research UK, Cambridge University Hospitals, Genentech/Roche, and the University of Adelaide underscore Microbiotica's commitment to forging impactful partnerships in advancing their initiatives. Their most recent milestone includes a Venture Round investment on 27th August 2024, with participation from notable investors such as Seventure Partners, IP Group, Cambridge Innovation Capital, British Patient Capital, Tencent, and Flerie Invest. The company's focus on harnessing the microbiome's potential in the medical landscape, coupled with strategic partnerships and robust investor support, positions Microbiotica as an intriguing player in the biotechnology and health care sectors.

Business keywords: Microbiome, Biotech, Research, Clinical Trials, Cancer, Oncology, Immuno-oncology, IBD, Microbiology, Therapeutics, Cell Biology, Bioinformatics

Services & Products

Development and commercialization of clinic-ready defined live biotherapeutic products for immuno-oncology and inflammatory bowel disease

Target Customers

Patients suffering from immuno-oncology and inflammatory bowel diseases healthcare providers pharmaceutical companies and research institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 6
Seventure Partners IP Group Cambridge Innovation Capital
Seventure Partners, IP Group +4
27 Aug 2024
Series B £50.00M 6
Seventure Partners IP Group Cambridge Innovation Capital
Seventure Partners, IP Group +4
07 Feb 2022
Venture Round £4.00M 1
Seventure Partners
Seventure Partners
24 Oct 2018
Seed Round £8.00M 2
IP Group Cambridge Innovation Capital
IP Group, Cambridge Innovation Capital
19 Dec 2016

Latest News

View All
Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer... — Eu-startups
Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients
Eu-startups Oct 16, 2026

Microbiotica Alternatives & Competitors

View All Alternatives
Microbiotica vs
OncoResponse
OncoResponse United States

Interrogating for Cures

10 employees
Biopharma, Biotechnology
Compare Microbiotica vs OncoResponse
Microbiotica vs
Merus N.V.
Merus N.V. The Netherlands

Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guideline...

Post-IPO Equity
185 employees
Biotechnology, Health Care
Compare Microbiotica vs Merus N.V.
Microbiotica vs
Persephone Biosciences
Persephone Biosciences United States

We are a synthetic biology company developing a platform to industrialize and scale the microbiome.

Seed
22 employees
AI, Biotechnology
View all alternatives

FAQ About Microbiotica

The microbiome is a new approach to medicine, offering potential for significant advancements. Microbiotica aims to remove translation challenges.
Microbiotica was founded in 2016.
Microbiotica is headquartered in Cambridge, United Kingdom.
Microbiotica operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Microbiome, Biotech, Research and Clinical Trials. Its customers include Patients suffering from immuno-oncology and inflammatory bowel diseases, healthcare providers and pharmaceutical companies.
Microbiotica has approximately 49 employees.
Microbiotica has completed 4 funding rounds, raising a total of $62.00M. The latest funding stage is Venture round.
Microbiotica offers: Development and commercialization of clinic-ready defined live biotherapeutic products for immuno-oncology and inflammatory bowel disease.
Top alternatives and competitors to Microbiotica include OncoResponse, Merus N.V., Persephone Biosciences, Kiromic Biopharma, Inc., Sensei Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Microbiotica and OncoResponse are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Microbiotica , https://bouncewatch.com/company/microbiotica, updated 24 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes